辅助帕博利珠单抗对比大剂量干扰素或伊匹木单抗对已切除黑色素瘤患者生活质量结局的有效性:SWOG S1404随机临床试验的二次分析
该研究为SWOG S1404 3期随机临床试验的二次分析,比较已切除高危黑色素瘤患者辅助帕博利珠单抗与标准治疗(伊匹木单抗或大剂量干扰素α-2b)的生活质量。832例可评估患者中,帕博利珠单抗组第3周期FACT-BRM TOI评分较伊匹木单抗/HDI组调整后高9.6分(95%CI 7.9-11.3;P<.001),超过预设临床意义差值。
要点
- 帕博利珠单抗组第3周期FACT-BRM TOI评分较伊匹木单抗/HDI组调整后高9.6分(95%CI 7.9-11.3;P<.001)。
- 线性混合模型中,至第7周期帕博利珠单抗组生活质量差异均超过5分且利于帕博利珠单抗。
- 事后分析中,帕博利珠单抗组FACT-BRM TOI评分优于伊匹木单抗亚组(差值6.0分;95%CI 4.1-7.8;P<.001)和HDI亚组(差值17.0分;95%CI 14.6-19.4;P<.001)。
核心结论
- 该3期随机临床试验的二次分析发现,在高危已切除黑色素瘤患者中,辅助帕博利珠单抗较辅助伊匹木单抗或HDI改善生活质量。
研究设计与样本
- SWOG癌症研究网络在美国、加拿大和爱尔兰的211个社区/学术中心开展的S1404 3期随机临床试验,患者于2015年12月至2017年10月入组,该生活质量子研究数据分析于2022年3月完成。
- 共832例患者可评估主要生活质量终点,患者按1:1随机分配至辅助帕博利珠单抗组或标准治疗(伊匹木单抗/HDI)组。
- 生活质量在基线及随机后第1、3、5、7、9周期使用FACT-BRM、FACT-General、FACT-Diarrhea和EQ-5D-3L量表评估,主要终点为第3周期FACT-BRM试验结局指数(TOI)评分的组间比较(线性回归)。
主要发现
- 1303例合格患者中位(范围)年龄56.7(18.3-86.0)岁,女性524例(40.2%),男性779例(59.8%);亚裔10例(0.8%)、黑人7例(0.5%)、西班牙裔44例(3.4%)、白人1243例(95.4%)。
- 1188例(91.1%)有基线FACT-BRM TOI评分,832例第3周期可评估(伊匹木单抗/HDI组267例[32.1%];帕博利珠单抗组565例[67.9%])。
- 第3周期FACT-BRM TOI依从率两组无差异(伊匹木单抗/HDI组96.0% vs 帕博利珠单抗组98.3%;P=.25)。
- 第3周期FACT-BRM TOI调整后评分帕博利珠单抗组较伊匹木单抗/HDI组高9.6分(95%CI 7.9-11.3;P<.001),超过预设临床意义差值。
- 线性混合模型中,至第7周期帕博利珠单抗组生活质量差异均超过5分且利于帕博利珠单抗;事后分析中,帕博利珠单抗组FACT-BRM TOI评分优于伊匹木单抗亚组(差值6.0分;95%CI 4.1-7.8;P<.001)和HDI亚组(差值17.0分;95%CI 14.6-19.4;P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL). OBJECTIVE: To compare QOL in patients with resected melanoma at high risk for relapse who were treated with adjuvant pembrolizumab vs standard of care with either ipilimumab or high-dose interferon α 2b (HDI). DESIGN, SETTING, AND PARTICIPANTS: The S1404 phase 3 randomized clinical trial was conducted by the SWOG Cancer Research Network at 211 community/academic sites in the US, Canada, and Ireland. Patients were enrolled from December 2015 to October 2017. Data analysis for this QOL substudy was completed in March 2022. Overall, 832 patients were evaluable for the primary QOL end point. INTERVENTIONS: Patients were randomized (1:1) to treatment with adjuvant pembrolizumab vs standard of care with ipilimumab/HDI. MAIN OUTCOMES AND MEASURES: Quality of life was assessed for patients at baseline and cycles 1, 3, 5, 7, and 9 after randomization using the Functional Assessment of Cancer Therapy (FACT) Biological Response Modifiers (FACT-BRM), FACT-General, Functional Assessment of Chronic Illness Therapy-Diarrhea, and European QOL 5-Dimension 3-Level scales. The primary end point was the comparison by arm of cycle 3 FACT-BRM trial outcome index (TOI) scores using linear regression. Linear-mixed models were used to evaluate QOL scores over time. Regression analyses included adjustments for the baseline score, disease stage, and programmed cell death ligand 1 status. A clinically meaningful difference of 5 points was targeted. RESULTS: Among 1303 eligible patients (median [range] age, 56.7 [18.3-86.0] years; 524 women [40.2%]; 779 men [59.8%]; 10 Asian [0.8%], 7 Black [0.5%], 44 Hispanic [3.4%], and 1243 White [95.4%] individuals), 1188 (91.1%) had baseline FACT-BRM TOI scores, and 832 were evaluable at cycle 3 (ipilimumab/HDI = 267 [32.1%]; pembrolizumab = 565 [67.9%]). Evaluable patients were predominantly younger than 65 years (623 [74.9%]) and male (779 [58.9%]). Estimates of FACT-BRM TOI cycle 3 compliance did not differ by arm (ipilimumab/HDI, 96.0% vs pembrolizumab, 98.3%; P = .25). The adjusted cycle 3 FACT-BRM TOI score was 9.6 points (95% CI, 7.9-11.3; P < .001) higher (better QOL) for pembrolizumab compared with ipilimumab/HDI, exceeding the prespecified clinically meaningful difference. In linear-mixed models, differences by arm exceeded 5 points in favor of pembrolizumab through cycle 7. In post hoc analyses, FACT-BRM TOI scores favored the pembrolizumab arm compared with the subset of patients receiving ipilimumab (difference, 6.0 points; 95% CI, 4.1-7.8; P < .001) or HDI (difference, 17.0 points; 95% CI, 14.6-19.4; P < .001). CONCLUSIONS AND RELEVANCE: This secondary analysis of a phase 3 randomized clinical trial found that adjuvant pembrolizumab improved QOL vs treatment with adjuvant ipilimumab or HDI in patients with high-risk resected melanoma. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02506153.
引用
- Unger JM, Darke A, Othus M, et al. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 36416836. doi:10.1001/jamaoncol.2022.5486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。